Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
Akshay S. Desai(Brigham and Women's Hospital), Doja Akande, Naresh Aggarwal, Armando Acosta Ruiz, Buki Ajala, Maria Acuna, Alexander Abitbol, Nune Makarova(Alnylam Pharmaceuticals (United States)), Sajeel Ahmed, John Agaiby, Mahmud Abdulkadir, Vishal Aggarwal, Andrea Havasi(Boston University), Saiaf Abdallah, Manish Saxena(Barts Health NHS Trust), Rafik Abadier, Ahmad Aswad, Nicole Abels, Jolita Badarienė(Vilnius University), Daniel Stiglitz(Alnylam Pharmaceuticals (United States)), Adam Karns(Cardiovascular Medical Group), Farhana Kazi(Baylor Medical Center at Garland), Marwa H. Ahmed, Puneet Agarwal, Joanna Abbott, Marìa Fernanda Troncoso Acevedo, Jessica Achan, Olga Lucía Acosta(Ankara Spine Center), Joel M. Neutel(Orange County Research Center), Dion Zappe(Alnylam Pharmaceuticals (United States)), Khaled Abouollo, Irene Acacio, Uriel Acevedo Gomez, Uriel-salvador Acevedo Gomez, Sheyla Acevedo, Olajide Adeniran, Tobi Adeyemi, Belen Adlawan, Amir Afzul, Wansu Park(Alnylam Pharmaceuticals (United States)), Eva Agaiby, Virginia Agustin, Emily Ailey, Bridget Aire, Antonina Agafonova-Tužikova, Shrey Acharya
Cited by 33
Related Papers
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial
|The Lancet Diabetes & Endocrinology|2017|295
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant
|The Journal of Infectious Diseases|2016|67
Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension
|JAMA|2025|65
Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25‐year longitudinal study
|American Journal of Hematology|2022|41